- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NPPA panel fixes retail price of Zuventus antihypertensive FDC Efonidipine, telmisartan, details
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) panel has fixed the retail price of uncoated bilayered tablet containing Efonidipine hydrochloride ethanolate 20mg and telmisartan IP 40mg manufactured and marketed by Zuventus Healthcare.
The retail price of uncoated bilayered tablet containing Efonidipine hydrochloride ethanolate 20mg and telmisartan IP 40mg for Zuventus Healthcare has been set at Rs 15.67 per tablet excluding GST
The recommendation came during the 39th meeting of the Multidisciplinary Committee of Experts held on February 25,2022, under the convenorship of Shri Manmohan Sachdeva, Advisor (Cost), through video-conferencing.
The issue of retail price fixation of uncoated bilayered tablet containing Efonidipine hydrochloride ethanolate 20mg and telmisartan IP 40mg for Zuventus Healthcare Ltd under Para 5 of DPCO 2013 was analysed at the meeting.
Fixed-dosed combination regimen consisting of a Efonidipine Hydrochloride Ethanolate and Telmisartan represent a new addition to the available antihypertensive treatment options. This combination has a better efficacy, defined by time to reach blood pressure targets as well as levels of blood pressure achieved, compared with the individual drugs. The combination is well tolerated, including in patients with stage 2 hypertension and the elderly.
After detailed deliberation, the committee recommended that the retail price of each uncoated bilayered tablet containing Efonidipine hydrochloride ethanolate 20mg and telmisartan IP 40mg for Zuventus Healthcare at Rs 15.67 per tablet excluding GST as detailed below.
Computation of Retail Price per Tablet | Source/ Method | |
Composition-Each uncoated bilayered tablet containing Efonidipine Hydrochloride Ethanolate 40 mg + Telmisartan IP 40 mg | ||
a.Efonidipine Hydrochloride Ethanolate 40 mg(Calculated as per Para 4 of DPCO 2013) | Retail price(as per June,2021 data) | 10.38 |
B. Telmisartan IP 40 mg | Ceiling Price(as per notification no .1330€ dated 25th March,2021. | 6.61 |
Worked out Retail Price(a+b) | 16.99 | |
c.Less 20% of the lowest of (a) and (b) as recommended win the pronab Sen Committee report | 1.32 | |
Net Retail Price (a+b+c) (per tablet excluding GST) | 15.67 | |
Company Claimed Price excluding GST (per tablet) | 19.20 | |
Recommended price excluding GST (per tablet) | 15.67 |
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.